The MF CD34+ population had most differentially methylated CpG sites and, according to the pathway analyses, the genes with differentially methylated CpG sites were involved in ‘hematopoietic differentiation’, ‘cell-cycle’, ‘cell death and survival’, and ‘cancer’, probably contributing to the increased proliferation and dedifferentiation observed in these cells. The gene discussed is CD34; the disease is cancer.